10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Review of methods for detecting glycemic disorders.

      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26
      Diabetes research and clinical practice
      Elsevier BV
      Biomarkers, Cardiovascular disease, Continuous glucose monitoring, Glycemic variability, HbA1c, Metabolomics, Oral glucose tolerance test, Prediabetes, Type 2 diabetes

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Prediabetes (intermediate hyperglycemia) consists of two abnormalities, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) detected by a standardized 75-gram oral glucose tolerance test (OGTT). Individuals with isolated IGT or combined IFG and IGT have increased risk for developing type 2 diabetes (T2D) and cardiovascular disease (CVD). Diagnosing prediabetes early and accurately is critical in order to refer high-risk individuals for intensive lifestyle modification. However, there is currently no international consensus for diagnosing prediabetes with HbA1c or glucose measurements based upon American Diabetes Association (ADA) and the World Health Organization (WHO) criteria that identify different populations at risk for progressing to diabetes. Various caveats affecting the accuracy of interpreting the HbA1c including genetics complicate this further. This review describes established methods for detecting glucose disorders based upon glucose and HbA1c parameters as well as novel approaches including the 1-hour plasma glucose (1-h PG), glucose challenge test (GCT), shape of the glucose curve, genetics, continuous glucose monitoring (CGM), measures of insulin secretion and sensitivity, metabolomics, and ancillary tools such as fructosamine, glycated albumin (GA), 1,5- anhydroglucitol (1,5-AG). Of the approaches considered, the 1-h PG has considerable potential as a biomarker for detecting glucose disorders if confirmed by additional data including health economic analysis. Whether the 1-h OGTT is superior to genetics and omics in providing greater precision for individualized treatment requires further investigation. These methods will need to demonstrate substantially superiority to simpler tools for detecting glucose disorders to justify their cost and complexity.

          Related collections

          Author and article information

          Journal
          Diabetes Res Clin Pract
          Diabetes research and clinical practice
          Elsevier BV
          1872-8227
          0168-8227
          Jul 2020
          : 165
          Affiliations
          [1 ] NYU School of Medicine, NYU Diabetes Prevention Program, Endocrinology, Diabetes, Metabolism, VA New York Harbor Healthcare System, Manhattan Campus, 423 East 23rd Street, Room 16049C, NY, NY 10010, USA. Electronic address: Michael.Bergman@nyumc.org.
          [2 ] Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. Electronic address: abdulghani@uthscsa.edu.
          [3 ] Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. Electronic address: defronzo@uthscsa.edu.
          [4 ] Research Area for Multifactorial Diseases, Bambino Gesù Children Hospital, Rome, Italy. Electronic address: melania.manco@opbg.net.
          [5 ] Department of Clinical and Molecular Medicine, University of Rome Sapienza, Rome 00161, Italy.
          [6 ] Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, Catanzaro 88100, Italy. Electronic address: vanessa.fiorentino@hotmail.it.
          [7 ] Department of Cardiovascular and Metabolic Diseases, Istituto Ricerca Cura Carattere Scientifico Multimedica, Sesto, San Giovanni (MI), Italy. Electronic address: antonio.ceriello@hotmail.it.
          [8 ] Emory University School of Medicine, Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Atlanta VA Health Care System, Atlanta, GA 30322, USA. Electronic address: mrhee@emory.edu.
          [9 ] Emory University School of Medicine, Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Atlanta VA Health Care System, Atlanta, GA 30322, USA. Electronic address: lawrence.phillips@emory.edu.
          [10 ] Diabetes Endocrinology and Obesity Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: stephanie.chung@nih.gov.
          [11 ] Diabetes Endocrinology and Obesity Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: celeste.cravalho@nih.gov.
          [12 ] Emory University School of Medicine, Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Atlanta VA Health Care System, Atlanta, GA 30322, USA. Electronic address: ram.jagannathan@emory.edu.
          [13 ] Institute of Clinical Research, University of Montpellier, Montpellier, France. Electronic address: louis.monnier@inserm.fr.
          [14 ] Institute of Clinical Research, University of Montpellier, Montpellier, France. Electronic address: dr.claudecolette@gmail.com.
          [15 ] Diabetes Research Group, Institute of Life Science, Swansea University, Wales, UK. Electronic address: owensdr@cardiff.ac.uk.
          [16 ] University Hospital of Pisa, Section of Metabolic Diseases and Diabetes, University Hospital, University of Pisa, Pisa, Italy. Electronic address: cribianchi@hotmail.com.
          [17 ] Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: stefano.delprato@med.unipi.it.
          [18 ] Endocrine, Cardiovascular & Metabolic Research, Unit for Multidisciplinary Research in Biomedicine (UMIB), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal. Electronic address: mpmonteiro@icbas.up.pt.
          [19 ] Department of Surgery and Physiology, Cardiovascular Research and Development Center, Faculty of Medicine, University of Porto, Porto, Portugal; Department of Endocrinology, Diabetes and Metabolism, São João University Hospital Center, Porto, Portugal. Electronic address: jsneves@med.up.pt.
          [20 ] Porto University, Porto Medical School, Porto, Portugal.
          [21 ] CEDOC-Centro de Estudos de Doenças Crónicas, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal; APDP-Diabetes Portugal, Education and Research Center (APDP-ERC), Lisboa, Portugal. Electronic address: paula.macedo@nms.unl.pt.
          [22 ] Institute for Biomedicine, Department of Medical Sciences, University of Aveiro, APDP Diabetes Portugal, Education and Research Center (APDP-ERC), Aveiro, Portugal. Electronic address: rogerio.ribeiro@apdp.pt.
          [23 ] CEDOC-Centro de Estudos de Doenças Crónicas, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal; APDP-Diabetes Portugal, Education and Research Center (APDP-ERC), Lisboa, Portugal. Electronic address: filipe.raposo@sapo.pt.
          [24 ] NYU School of Medicine, Division of Endocrinology, Diabetes, Metabolism, NY, NY 10016, USA. Electronic address: brenda.dorcely@nyulangone.org.
          [25 ] NYU School of Medicine, Division of Endocrinology, Diabetes, Metabolism, NY, NY 10016, USA. Electronic address: nouran.ibrahim@nyulangone.org.
          [26 ] Department of Endocrinology and Diabetology, Université Catholique de Louvain, University Clinic Saint-Luc, Brussels, Belgium. Electronic address: martin.buysschaert@uclouvain.be.
          Article
          S0168-8227(20)30483-6
          10.1016/j.diabres.2020.108233
          32497744
          11091e20-bb8b-4f1d-bd7b-e34372cde632
          History

          Continuous glucose monitoring,Prediabetes,Oral glucose tolerance test,Metabolomics,HbA1c,Glycemic variability,Cardiovascular disease,Biomarkers,Type 2 diabetes

          Comments

          Comment on this article